FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, D. | .C. 20549 |
|----------------|-----------|
|----------------|-----------|

|     | OMB APPROVAL        |           |  |  |  |  |  |  |  |  |  |
|-----|---------------------|-----------|--|--|--|--|--|--|--|--|--|
|     | OMB Number:         | 3235-0287 |  |  |  |  |  |  |  |  |  |
|     | Estimated average b | urden     |  |  |  |  |  |  |  |  |  |
| - 1 | hours per response. | 0.5       |  |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Isacson Ole</u>                           |  |            |  |               | 2. Issuer Name and Ticker or Trading Symbol <u>Cyclerion Therapeutics, Inc.</u> [ CYCN ] |      |  |  |   |                              |                           |  |  | ationship of all applic | able)   | g Pers   | son(s) to Issi                                      |  |  |
|---|--|------------|--|---------------|--|------|--|--|---|------------------------------|---------------------------|--|--|-------------------------|---|--|---|--|--|
| (Last) (First) (Middle) C/O CYCLERION THERAPEUTICS, INC. 245 FIRST STREET, 18TH FLOOR |  |            |  | 06            | 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2022                              |      |  |  |   |                              |                           |  |  | Officer<br>below)       | icer (give title<br>ow)   |  | Other (s<br>below)                                  | pecify   |  |
| (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)                                      |  |            |  | -   4. I<br>- | If Amendment, Date of Original Filed (Month/Day/Year)                                    |      |  |  |   |                              |                           | 6.<br>Lir                                |  | ′                       |   |  |   |  |  |
|   |  | Tak        | le I - Nor   | n-Deriv       | vativ  | e Se | curities   | s Ac   | quired, C   | Disp                         | osed o                    | f, or Be                                 | neficia                                | lly (                   | Owned   |  |   |  |  |
| 1. Title of Security (Instr. 3)  2. Transa Date (Month/D.                             |  |            |  |               | 2A. Deemed<br>Execution Date,  |      |  | 3. 4. Securities Ac<br>Transaction Code (Instr. 5) |   | ties Acquir<br>I Of (D) (Ins | ed (A) or<br>str. 3, 4 an | or 5. Amou<br>4 and Securiti<br>Benefici |  | s<br>ally<br>ollowing   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | : Direct<br>r Indirect<br>str. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |  |  |
|   |  |            |  |               |  |      |  | Code   | v   | Amount                       | (A) o                     | Price                                    |  | Transact<br>(Instr. 3 a | tion(s)   |  |   | (Instr. 4)   |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |            |  |               |  |      |  |  |   |                              |                           |  |  |                         |   |  |   |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  |            | 3A. Deemed<br>Execution Da<br>if any<br>(Month/Day/Y | Date,         | 4.<br>Transa<br>Code (<br>8)   |      | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |  | 6. Date Exercisa<br>Expiration Date<br>(Month/Day/Yea |                              | of Securities             |  | ies<br>g<br>Security                   | D                       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)               | 9. Number<br>derivative<br>Securities<br>Beneficial<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Ow<br>For<br>Illy Dire<br>or I                      | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |            |  |               | Code   | v    | (A)  | (D)  | Date<br>Exercisable                                   |                              | xpiration<br>ate          | Title                                    | Amount<br>or<br>Number<br>of<br>Shares |                         |   |  |   |  |  |
| Stock<br>Option<br>(Right to<br>Buy)  | \$0.53   | 06/14/2022 |  |               | Α  |      | 20,000   |  | (1)   | 0                            | 6/14/2032                 | Common<br>Stock                          | 20,000                                 |                         | \$0   | 20,000   | 0   | D  |  |

## **Explanation of Responses:**

1. The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

/s/ Gary J. Simon, Attorney-in-

**Fact** 

06/16/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.